Rituximab biosimilar - Hetero Drugs

Drug Profile

Rituximab biosimilar - Hetero Drugs

Alternative Names: Maball; Rituximab (Hetero)

Latest Information Update: 09 Sep 2015

Price : $50

At a glance

  • Originator Hetero Drugs
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 05 Aug 2015 Launched for Chronic lymphocytic leukaemia (Combination therapy, First-line therapy) in India (IV)
  • 05 Aug 2015 Launched for Diffuse large B cell lymphoma (Combination therapy, First-line therapy) in India (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top